{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(11)"],"submitter":["Cazaubon Y"],"pubmed_abstract":["Mitotane is the most effective agent in post-operative treatment of adrenocortical carcinoma. In adults, the starting dose is 2-3 g/day and should be slightly increased to reach the therapeutic index of 14-20 mg/L. This study developed a population PK model for mitotane and to simulate recommended/high dosing regimens. We retrospectively analyzed the data files of 38 patients with 503 plasma concentrations for the pharmacokinetic analysis. Monolix version 2019R1 was used for non-linear mixed-effects modelling. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA ≥ 14 mg/L) at one month and at three months. Mitotane concentration data were best described by a linear one-compartment model. The estimated PK parameters (between-subject variability) were:"],"journal":["Pharmaceutics"],"pagination":["E566"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6920765"],"repository":["biostudies-literature"],"pubmed_title":["Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?"],"pmcid":["PMC6920765"],"pubmed_authors":["Konecki C","Cazaubon Y","Talineau Y","Djerada Z","Russello J","Mathieu O","Feliu C"],"additional_accession":[]},"is_claimable":false,"name":"Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?","description":"Mitotane is the most effective agent in post-operative treatment of adrenocortical carcinoma. In adults, the starting dose is 2-3 g/day and should be slightly increased to reach the therapeutic index of 14-20 mg/L. This study developed a population PK model for mitotane and to simulate recommended/high dosing regimens. We retrospectively analyzed the data files of 38 patients with 503 plasma concentrations for the pharmacokinetic analysis. Monolix version 2019R1 was used for non-linear mixed-effects modelling. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA ≥ 14 mg/L) at one month and at three months. Mitotane concentration data were best described by a linear one-compartment model. The estimated PK parameters (between-subject variability) were:","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2026-05-04T08:14:00.966Z","creation":"2020-05-22T00:42:04Z"},"accession":"S-EPMC6920765","cross_references":{"pubmed":["31683663"],"doi":["10.3390/pharmaceutics11110566"]}}